News
15h
ZME Science on MSNMice Lived 30% Longer (And Better) on This Drug Combo and Scientists Are Eyeing Human Trials NextIn a new study out this week, scientists report that a combination of two existing cancer drugs — rapamycin and trametinib — ...
A dedication to innovation – the translation of ideas into impact – is driving powerful benefits at McMaster University (Mac) in Hamilton, Ont., as part of a vision for bolstering economic growth and ...
4h
News-Medical.Net on MSNWhat drives insulin resistance? Proteomics reveals key pathways in human skeletal muscleIdentifying proteomic signatures of insulin resistance in fasting muscle offers insights for personalized type 2 diabetes ...
18hon MSN
A new concept of kinetic modules in biochemical networks could revolutionize the understanding of how these networks function ...
Imagine cells navigating through a complex maze, guided by chemical signals and the physical landscape of their environment.
Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...
The effects of obesity on cancer treatment efficacy remain unclear, as both beneficial and detrimental modulations of the tumor immune microenvironment have been reported. We compared 68Ga-NOTA-GZP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results